Technical Analysis for ADRO - Aduro Biotech, Inc.

Grade Last Price % Change Price Change
grade B 3.77 4.72% 0.17
ADRO closed down 1.37 percent on Wednesday, February 19, 2020, on 1.57 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up
Historical ADRO trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 4.72%
Wide Bands Range Expansion 4.72%
Overbought Stochastic Strength 4.72%
Golden Cross Bullish 3.29%
Wide Bands Range Expansion 3.29%
Overbought Stochastic Strength 3.29%
Up 3 Days in a Row Strength 3.29%
Up 4 Days in a Row Strength 3.29%
Up 5 Days in a Row Strength 3.29%
Wide Bands Range Expansion 11.54%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company's cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Medicine Cancer Cancer Immunotherapy Technology Platforms Metastatic Pancreatic Cancer Johnson & Johnson Lung Cancers

Is ADRO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.59
52 Week Low 0.9
Average Volume 1,359,697
200-Day Moving Average 1.59
50-Day Moving Average 1.65
20-Day Moving Average 2.33
10-Day Moving Average 3.06
Average True Range 0.28
ADX 59.95
+DI 46.93
-DI 4.00
Chandelier Exit (Long, 3 ATRs ) 2.97
Chandelier Exit (Short, 3 ATRs ) 2.16
Upper Bollinger Band 3.92
Lower Bollinger Band 0.73
Percent B (%b) 0.9
BandWidth 136.89
MACD Line 0.56
MACD Signal Line 0.43
MACD Histogram 0.1337
Fundamentals Value
Market Cap 268.6 Million
Num Shares 74.6 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -2.31
Price-to-Sales 35.46
Price-to-Book 2.36
PEG Ratio 0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.37
Resistance 3 (R3) 4.35 4.07 4.24
Resistance 2 (R2) 4.07 3.88 4.08 4.19
Resistance 1 (R1) 3.84 3.76 3.70 3.86 4.15
Pivot Point 3.56 3.56 3.50 3.57 3.56
Support 1 (S1) 3.33 3.37 3.19 3.35 3.05
Support 2 (S2) 3.05 3.25 3.06 3.01
Support 3 (S3) 2.82 3.05 2.96
Support 4 (S4) 2.84